BioAge Labs (BIOA) EBITDA Margin (2025 - 2026)
BioAge Labs (BIOA) posted EBITDA Margin of 915.4% for Q1 2026, up 0.87% sequentially from 923.42% in Q4 2025, and up 21802.0% YoY from N/an in Q1 2025.
BioAge Labs (BIOA) EBITDA Margin (2025 - 2026) Analysis & Trends
BioAge Labs has reported EBITDA Margin for 2 years, with the latest figure at 915.4% in Q1 2026.
- Quarterly EBITDA Margin rose 21802.0% year-over-year to 915.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 985.93% (up 465342.0% YoY) and the FY2025 annual result came in at 1031.46%, changed N/A from the prior year.
- EBITDA Margin climbed to 915.4% in Q1 2026 per BIOA's latest filing, from 923.42% in the prior quarter.
- Over five years, EBITDA Margin peaked at 915.4% in Q1 2026 and troughed at 1133.43% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioAge Labs | 437.85 Mn | 437.85 Mn | -14.23 Mn | -1,196.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,196.78% |
| Mar 31, 2026 | -915.40% |
| Dec 31, 2025 | -923.42% |
| Sep 30, 2025 | -1,126.58% |
| Jun 30, 2025 | -1,026.99% |
| Mar 31, 2025 | -1,133.43% |